<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276623</url>
  </required_header>
  <id_info>
    <org_study_id>18/537</org_study_id>
    <nct_id>NCT04276623</nct_id>
  </id_info>
  <brief_title>Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment</brief_title>
  <official_title>Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study on ophthalmological comorbidities and the underlying pathomechanisms of conjunctivitis
      during dupilumab treatment in atopic dermatitis (AD) patients. Patients participate in the
      Bioday Registry.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship between goblet cell density and the incidence of conjunctivitis over time</measure>
    <time_frame>change of goblet cell density between baseline, 4 weeks and 28 weeks after start dupilumab, at the moment of the development of eye symptoms, 4 weeks after ocular treatment</time_frame>
    <description>Establish the relationship between goblet cell densitiy and the incidence of conjunctivitis during dupilumab treatment in AD patients. Goblet cell density will determined by counting the goblet cells. The amount of goblet cells will be compared at different time points. Goblet cells will be collected using Impression Cytology of the conjunctiva and will be stained directly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship between goblet cell density and the risk of conjunctivitis</measure>
    <time_frame>change of goblet cell density between baseline, 4 weeks and 28 weeks after start dupilumab, at the moment of the development of eye symptoms, 4 weeks after ocular treatment</time_frame>
    <description>Establish the relationship between goblet cell densitiy and the risk of conjunctivitis during dupilumab treatment in AD patients. Goblet cell density will determined by counting the goblet cells. The amount of goblet cells will be compared at different time points. Goblet cells will be collected using Impression Cytology of the conjunctiva and will be stained directly.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conjunctival changes during dupilumab treatment using Impression Cytology</measure>
    <time_frame>baseline, 4 weeks and 28 weeks after start dupilumab, at the moment of the development of eye symptoms, 4 weeks after ocular treatment</time_frame>
    <description>Better understanding of conjunctival changes using Impression Cytology of the conjunctiva, collected at different time points during treatment with dupilumab in AD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal treatment of conjunctivitis</measure>
    <time_frame>at the moment of the development of eye symptoms, 4 weeks after ocular treatment</time_frame>
    <description>Establish the most optimal treatment of conjunctivitis during dupilumab treatment. Ophthalmological examination will be compared at all time points to determine if the prescribed therapy is effective and optimal.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atopic Dermatitis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, tear fluid, impression cytology of the conjunctiva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with atopic dermatitis indicated for dupilumab, without current use of oral
        immunosuppressive treatment .
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with atopic dermatitis indicated for dupilumab, without current use of
             oral immunosuppressive treatment .

        Exclusion Criteria:

          -  Treatment with oral or ocular immunosuppressive drugs 2 weeks prior to start of
             dupilumab treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roselie Achten, MD</last_name>
    <phone>0031 88 75 57439</phone>
    <email>r.e.achten@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marjolein de Bruin-Weller, MD, PhD</last_name>
    <email>m.s.debruin-weller@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M S de Bruin-Weller, MD, PhD</last_name>
      <phone>+31 88 755 7388</phone>
      <email>m.s.debruin-weller@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>M S de Bruin-Weller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>R E Achten, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Dr M.S. de Bruin-Weller</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Dupilumab</keyword>
  <keyword>Dupixent</keyword>
  <keyword>Conjunctivitis</keyword>
  <keyword>Bioday</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

